WO2004089942A2 - Derives de benzimidazolidinone utilises en tant qu'agents muscariniques - Google Patents

Derives de benzimidazolidinone utilises en tant qu'agents muscariniques Download PDF

Info

Publication number
WO2004089942A2
WO2004089942A2 PCT/US2004/009859 US2004009859W WO2004089942A2 WO 2004089942 A2 WO2004089942 A2 WO 2004089942A2 US 2004009859 W US2004009859 W US 2004009859W WO 2004089942 A2 WO2004089942 A2 WO 2004089942A2
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
optionally substituted
group
nmr
compound
Prior art date
Application number
PCT/US2004/009859
Other languages
English (en)
Other versions
WO2004089942A3 (fr
Inventor
Nicholas Michael Kelly
Kristian Norup Koch
Bo-Ragnar Tolf
Original Assignee
Acadia Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/262,517 external-priority patent/US7087593B2/en
Priority claimed from US10/408,192 external-priority patent/US6951849B2/en
Application filed by Acadia Pharmaceuticals Inc. filed Critical Acadia Pharmaceuticals Inc.
Publication of WO2004089942A2 publication Critical patent/WO2004089942A2/fr
Publication of WO2004089942A3 publication Critical patent/WO2004089942A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Definitions

  • Novel benzimidazolidinone derivatives have been prepared and identified as having high affinity for muscarinic Mi and M 4 receptors. The treatment of mental disorders associated with increasing the activity of a cholinergic receptor using these novel compounds is anticipated. Moreover, these compounds also have dopamine D 2 antagonist activity, rendering them particularly interesting as anti-psychotic agents.
  • Muscarinic cholinergic receptors mediate the actions of the neurotransmitter acetylcholine in the central and peripheral nervous systems. Muscarinic receptors play a critical role in the central nervous system mediating higher cognitive functions, as well as in the peripheral parasympathetic nervous system where they mediate cardiac, respiratory, digestive, and endocrine and exocrine responses. Five distinct muscarinic receptor subtypes have been identified, M ⁇ -M 5 .
  • the muscarinic Mi receptor subtype is predominantly expressed in the cerebral cortex and is believed to be involved in the control of higher cognitive functions; the M 2 receptor is the predominant subtype found in heart and is involved in the control of heart rate; the M 3 receptor is widely expressed in many peripheral tissues and is believed to be involved in gastrointestinal and urinary tract stimulation as well as sweating and salivation; the M receptor is present in brain and may be involved in locomotion; the M 5 , receptor is present in the brain where its role is at present poorly defined. Mi and M have been particularly associated with the dopaminergic system.
  • Conditions associated with cognitive impairment are accompanied by a reduction of acetylcholine content in the brain. This is believed to be the result of degeneration of cholinergic neurons of the basal forebrain, which widely innervate multiple areas of the brain, including the association cortices and hippocampus, that are critically involved in higher processes.
  • acetylcholine levels have focused on increasing levels of choline, the precursor for acetylcholine synthesis, and on blocking acetylcholineesterase (AChE), the enzyme that metabolizes acetylcholine. Attempts to augment central cholinergic function through the administration of choline or phosphatidylcholine have not been successful.
  • AChE inhibitors have shown therapeutic efficacy, but have been found to have frequent cholinergic side effects due to peripheral acetylcholine stimulation, including abdominal cramps, nausea, vomiting, and diarrhea. These gastrointestinal side effects have been observed in about a third of the patients treated.
  • AChE inhibitors such as tacrine
  • tacrine have also been found to cause significant hepatotoxicity with elevated liver transaminases observed in about 30% of patients.
  • the adverse effects of AChE inhibitors have severely limited their clinical utility.
  • the dopamine hypothesis of schizophrenia suggests that increased dopamine neurotransmission underlies the positive symptoms of the disease and is supported by the evidence that dopamine receptor blockade is effective in ameliorating such psychotic symptoms.
  • drugs that enhance dopamine neurotransmission in the brain cause psychotic-like episodes in man and exacerbate psychotic symptoms in schizophrenic patients.
  • drugs that increase dopamine neurotransmission cause behavioural effects such as increased locomotion, climbing and deficits in prepulse inhibition.
  • dopamine receptor antagonists can block these behavioural effects.
  • dopamine receptor antagonists also cause severe extrapyramidal side effects in patients as predicted by induction of catalepsy in animal models. These extrapyramidal side effects include tremor, bradykinesia, akithesias, and tardive dyskinesias.
  • Mi receptor agonist activity Due in part to these observations, the discovery of agents with Mi receptor agonist activity has been sought after for the treatment of dementia. However, existing agents lack specificity in their actions at the various muscarinic receptor subtypes. Known Mi muscarinic agonists such as arecoline have also been found to be weak agonists of M 2 as well as M 3 receptor subtypes and are ineffective in the treatment of cognitive impairment, due in large part to their dose-limiting M 2 and M 3 receptor mediated side effects.
  • muscarinic agonists including xanomeline have been shown to be active in animal models with similar profiles to known antipsychotic drugs, but without causing catalepsy (Bymaster et al., Eur. J. Pharmacol. 1998, 356, 109, Bymaster et al., Life Sci. 1999, 64, 527, Shannon et al., J. Pharmacol. Exp. Ther. 1999, 290, 901, Shannon et al., Schizophrenia Res. 2000, 42, 249). Further, xanomeline was shown to reduce psychotic behavioural symptoms such as delusions, suspiciousness, vocal outbursts, and hallucinations in Alzheimer's disease patients (Bodick et al., Arch. Neurol. 1997, 54, 465), however treatment induced side effects that severely limit the clinical utility of this compound.
  • the present investigators have focussed their efforts on the development of a molecule that simultaneously reduced the positive symptoms and improved the negative symptoms and the cognitive impairments associated with schizophrenia as a novel treatment of mental disorders. It is the intent of the present investigators to demonstrate that muscarinic Mi and/or M agonists with combined D 2 antagonist activity may possess superior antipsychotic efficacy without the side effects associated with high dose D 2 antagonism alone. The D 2 antagonist properties of these molecules may contribute to a reduction in the positive symptoms of this disease.
  • the Mi and or M 4 agonist properties of these compounds may reduce the cognitive dulling and perhaps ameliorate other negative symptoms associated with schizophrenia.
  • This unique combination of central nervous system activities in one molecule is unprecedented and may lead to the development of an entirely new class of antipsychotic drugs, ones with the superior clinical properties without the limiting side-effect profile.
  • WO 99/32481 discloses derivatives including 1 -substituted benzimidazolones and derivatives thereof.
  • the compounds according to WO 99/32481 are intended for treatment of glaucoma, myopia, psychosis and various other conditions involving muscarinic receptors.
  • US 4,254,127 discloses l-(l-piperidinyl)alkyl-benzimidazolone derivatives wherein the piperidine is 4-substituted with aryl-alkyls, aryl-alkylcarbonyls, aryl-alkylcarbonyl derivatives, and aryl-alkoxides.
  • the compounds according to US 4,254,127 are reported to have psychotropic activity acting as serotonin antagonists.
  • US 5,789,425 and US 5,726,188 discloses 1-substituted imidazolidin-2-one derivatives with muscarinic Mi activity. Benzimidazolidinone derivatives are not disclosed therein.
  • WO 96/13262 disclose benzimidazolidin-2-one derivatives 1-subsituted with a
  • WO 97/16186 and US 5,718,912 disclose l-[cycloalkylpiperidin-4-yl]-2H- benzimidazolones as selective muscarinic agonists of the M 2 subtype with low activity at the M 3 subtype, and when utilised for glaucoma therapy have fewer side effects than pilocarpine therapy.
  • the present invention seeks to provide compounds which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the Mi and/or M 4 receptor subtypes as well as providing compounds aimed at the approach of treating psychosis using compounds which has a combined muscarinic agonist and dopamine antagonist profile.
  • the present invention relates to a compound of Formula I
  • X is selected from the group consisting of C, O, N and S
  • Z is selected from the group consisting of CH and N
  • SPU is a spacer unit providing a distance d between Z and N wherein
  • A is absent or an optionally substituted -C 3 .s-cycloalkyl
  • heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine, piperidine, pyrrolidine,
  • substituents R 4 independently selected from the group consisting of hydrogen, halogen, hydroxy, Cj.s-allcyl, C _- heteroalkyl, C 3 . 8 -cycloalkyl, C 3 . 8 -
  • R is selected from the group consisting of hydrogen, halogen, hydroxy, C ⁇ . 8 -alkyl, C ⁇ _ 8 - heteroalkyl, C ⁇ . 8 -alkoxy, C 3 . 8 -cycloalkyl, C 3 . 8 -heterocyclyl, C ⁇ . 8 -alkylcarbonyl, C ⁇ . 8 -alkylidene, C 2 - 8 - alkenyl and C 2 _ 8 -alkynyl;
  • R 3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted C ⁇ . 8 -alkyl, C ⁇ profession 8 -alkoxy, optionally substituted C ⁇ -alkylidene, optionally substituted C 2 . 8 -alkenyl, optionally substituted C 2 . 8 -alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 . 8 -cycloall yl, optionally substituted C 3 . 8 -heterocyclyl, and optionally substituted C ⁇ .
  • each R 6 and each R 7 is optionally and independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C ⁇ _ 8 -alkyl, C ⁇ _ 8 -alkoxy, optionally substituted C ⁇ . 8 -allcylidene, optionally substituted C 2 . 8 -alkenyl, optionally substituted C 2 . 8 -alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 . 8 -cycloall yl, optionally substituted C 3 . 8 -heterocyclyl, optionally substituted C ⁇ .
  • a second aspect of the invention relates to a method of increasing an activity of a cholinergic receptor comprising contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound of Formula I.
  • an increase in activity of the cholinergic receptor and the cholinergic system is, as discussed supra, associated to the activity of anti-psychotics. Accordingly, further aspects of the present invention relate to a method of treating or preventing a mental disorder in a mammal, comprising the administration of an effective amount of a compound of Formula I and to the use of a compound of Formula I, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the preparation of a medicament for the prophylactic or curative treatment of psychosis or alleviation of symptoms of psychosis.
  • a mammal may be selected from the group consisting of mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, primates, such as monkeys, chimpanzees, and apes, and humans. Most preferably, the mammal is a human.
  • aspects of the invention relate to compounds of Formula I for use as selective modulators of Mi and/or M 4 muscarinic receptors for the treatment of disorders associated with muscarinic receptors and especially with said receptor subtypes.
  • compounds of Formula I have surprisingly been found to have selectivity for the Mi and M muscarinic receptor subtypes. Therapeutic advantages may be derived from this selectivity. Further therapeutic advantages may be derived from the concomitant muscarinic Mj and M 4 agonist activity and dopaminergic D 2 antagonist activity.
  • a further aspect of the present invention relates to a method of modulating or preventing the progression or fonnation of amyloid plaques in an individual susceptible to or affected by Alzheimer's Disease by administering an effective amount of a compound of Formula I, said effective amount sufficient to modulate amyloid precursor protein processing.
  • Figure 1 is a graph depicting the reduction of spontaneous locomotor activity in mice with the administration of 10 mg/kg i.p. of 6 IKS 19.
  • Figure 2 is a graph that shows the reduction of amphetamine-induced hyperactivity in mice with the administration of 3 and 10 mg/kg i.p. of 6 IKS 19
  • Figure 3 is a graph that shows the reduction of scopolamine-induced hyperactivity in mice with the administration of 1, 3 and 10 mg/kg i.p. of 61KS19
  • Figure 4 is a graph that shows the reduction of MK-801 -induced hyperactivity in mice with the administration of 10 mg/kg i.p. of 61KS19.
  • Figure 5 depicts the result of a comparison between haloperidol and 61KS19, and shows that unlike haloperidol, 61KS19 (10 mg/kg i.p.) failed to induce catalepsy.
  • the present invention relates to a compound of Formula I
  • X is selected from the group consisting of C, O, N and S Z is selected from the group consisting of CH and N
  • A is absent or an optionally substituted -C 3 . 8 -cycloalkyl
  • heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine, piperidine, pyrrolidine,
  • R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, .s-alkyl, C ⁇ _ 8 - heteroalkyl, C ⁇ _ 8 -alkoxy, C 3 Stamm 8 -cycloalkyl, C 3 . 8 -heterocyclyl, C ⁇ . 8 -alkylcarbonyl, C ⁇ _ 8 -alkylidene, C . 8 - alkenyl and C 2 _ 8 -alkynyl;
  • R 3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted C ⁇ _ 8 -alkyl, C ⁇ . 8 -alkoxy, optionally substituted C ⁇ _ 8 -alkylidene, optionally substituted C 2 . 8 -alkenyl, optionally substituted C 2 . 8 -alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 . 8 -cycloalkyl, optionally substituted C 3 .
  • each R 6 and each R 7 is optionally and independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C ⁇ . 8 -alkyl, C ⁇ . 8 -alkoxy, optionally substituted C ⁇ profession 8 -alkylidene, optionally substituted C 2 . 8 -alkenyl, optionally substituted C 2 . 8 -all ynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 . 8 -cycloalkyl, optionally substituted C 3 .
  • the scope of the present invention includes the R isomer free of any S isomer, the S isomer free of any R isomer, and the racemic mixture comprising both the R and the S isomers.
  • the scope of the present invention includes each diastereomer free of any of the other diastereomers, in addition to a mixture of the various diastereomers.
  • the scope of the present invention includes a sample comprising a compound of Formula I, wherein the sample is optically active or wherein the sample is optically inactive.
  • the alkenylene moiety may be either the E isomer or the Z isomer.
  • the scope of the present invention includes those embodiments comprising the E isomer, the embodiments comprising the Z isomer, and the embodiments comprising a mixture of the E and the Z isomers.
  • pharmaceutically acceptable salt refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound.
  • Pharmaceutical salts can be obtained by reacting a- compound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • Pharmaceutical salts can also be obtained by reacting a compound of the invention with a base to fonn a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N- methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
  • a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N- methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
  • a “prodrug” refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
  • An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
  • a further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
  • the term "selective” or “selectivity” is intended to mean the ability of a compound to generate a desired response from a particular receptor type, subtype, class or subclass while generating less or little response from other receptor types.
  • "Selective” or “selectivity” of an Mi or M 4 muscarinic agonist compound is intended to mean the ability of a compound to increase the activity of the Mi or M 4 muscarinic receptor, respectively, while causing non-substantial, little or no increase in the activity of other subtypes including M 3 and M 5 subtypes, and preferably the M 2 subtype.
  • Compounds of the presents invention may also show selectivity toward both Mi and M receptors, i.e. increase the activity of both the Mi and M 4 muscarinic receptors, while causing little or no increase in the activity of other subtypes including M 3 and M 5 subtypes, and preferably the M 2 subtype.
  • C ⁇ . 8 -alkyl is intended to mean a linear or branched saturated hydrocarbon chain wherein the longest chains has from one to eight carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl and octyl.
  • a branched hydrocarbon chain is intended to mean' a C ⁇ . 8 -alkyl substituted at any carbon with a hydrocarbon chain.
  • C 2 . 8 -alkenyl is intended to mean a linear or branched hydrocarbon group having from two to eight carbon atoms and containing one or more double bonds.
  • Illustrative examples of C 2 . 8 -alkenyl groups include allyl, homo-allyl, vinyl, crotyl, butenyl, pentenyl, hexenyl, heptenyl and octenyl.
  • C 2 - ⁇ o-alkenyl groups with more than one double bond include butadienyl, pentadienyl, hexadienyl, heptadienyl, hexatrienyl, heptatrienyl and octatrienyl groups as well as branched forms of these.
  • the position of the unsaturation (the double bond) may be at any position along the carbon chain.
  • C ⁇ tread 8 -alkylidene is intended to mean a linear or branched hydrocarbon chain radical wherein the longest chain has from one to eight carbon atoms and an unsaturated bond at the radical position. Bonds further than the radical position may also be unsaturated.
  • C 2 _ 8 -alkynyl is intended to mean linear or branched hydrocarbon groups containing from two to eight carbon atoms and containing one or more triple bonds.
  • Illustrative examples of C 2 . 8 -alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl and octynyl groups as well as branched forms of these.
  • the position of unsaturation (the triple bond) may be at any position along the carbon chain. More than one bond may be unsaturated such that the "C 2 _ 8 -alkynyl" is a di-yne or enedi-yne as is known to the person skilled in the art.
  • C 3 . 8 -cycloalkyl is intended to cover three-, four-, five-, six- seven-, and eight-membered rings comprising carbon atoms only whereas the term “heterocyclyl” is intended to mean three-, four-, five-, six- seven-, and eight-membered rings wherein carbon atoms together with from 1 to 3 heteroatoms constitute said ring.
  • the heteroatoms are independently selected from oxygen, sulphur, and nitrogen.
  • C 3 . 8 -cycloalkyl and heterocyclyl rings may optionally contain one or more unsaturated bonds situated in such a way, however, that an aromatic ⁇ -electron system does not arise.
  • Illustrative examples of preferred "C 3 . 8 -cycloalkyl" are the.
  • carbocycles cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene, 1,2- cycloheptadiene, 1,3-cycloheptadiene, 1 ,4-cycloheptadiene and 1,3,5 cycloheptatriene.
  • heterocyclyls are the heterocycles 2H-thipyran, 3H- thipyran, 4H-thipyran, tetrahydrothiopyran, 2H-pyran, 4H-pyran, tetrahydropyran, piperidine, 1,2- dithiin, 1,2-dithiane, 1,3-dithiin, 1,3-dithiane, 1,4-dithiin, 1,4-dithiane, 1,2-dioxin, 1,2-dioxane, 1,3- dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, piperazine, 1 ,2-oxathiin, 1 ,2-oxathiane, 4H-1,3- oxathiin, 1,3-oxathiane, 1,4-oxathiin, 1 ,4-oxathiane, 2H-l,2-thiazine,
  • aryl is intended to mean a carbocyclic aromatic ring or ring system.
  • C 5 . ⁇ 0 -aryl refers to an aryl group whose carbocyclic aromatic ring has five, six, seven, eight, nine, or ten carbon atoms.
  • aryl includes fused ring systems wherein at least two aryl rings, or at least one aryl and at least one C 3 . 8 - cycloalkyl, or at least one aryl and at least one heterocyclyl, share at least chemical bond.
  • aryl rings include optionally substituted phenyl, naphthalenyl, plienanthrenyl, anthracenyl, acenaphthylenyl, tetralinyl, fluorenyl, indenyl, indolyl, coumaranyl, coumarinyl, chromanyl, isochromanyl, and azulenyl.
  • a preferred aryl group is phenyl.
  • heteroaryl is intended to mean an aryl group where one or more carbon atoms in an aromatic ring have been replaced with one or more heteroatoms selected from the group comprising nitrogen, sulphur, phosphorous and oxygen.
  • heteroaryl comprises fused ring systems wherein at least one aryl ring and at least one heteroaryl ring, at least two heteroaryls, at least one heteroaryl and at least one heterocyclyl, or at least one heteroaryl and at least one C 3 _ 8 - cycloalkyl share at least one chemical bond, such as one or two chemical bonds.
  • a heteroaryl may be selected from the group comprising furanyl, thienyl, pyrrolyl, phenoxazonyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, isoxazolyl, imidazolyl isothiazolyl, oxadiazolyl, furazanyl, triazolyl, thiadiazolyl, piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl and triazinyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, benzopyrazolyl,indazolyl, benzimidazolyl, benzthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl,
  • C ⁇ . 8 -alkoxy is intended to mean C ⁇ . 8 -alkyl-oxy such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, isopentoxy, neopentoxy and hexoxy
  • C ⁇ . 6 -arylallyl refers to an allcyl group of 1 to 6 carbon atoms, which is substituted with an aryl group. Both the aryl group and the allcyl group may be optionally substituted, as described herein.
  • C ⁇ _ 8 -heteroalkyl refers to an alkyl group that comprises a heteroatom within the chain.
  • the term encompasses an alkoxyallcyl group, such as an ether (R-O-R'-), a thioether group (R-S-R'-), or an amidoalkyl group (R-NH-R'-).
  • halogen includes fluorine, chlorine, bromine and iodine.
  • salts is intended to mean pharmaceutically acceptable acid addition salts obtainable by treating the base form of a functional group, such as an amine, with appropriate acids such as inorganic acids, for example hydrohalic acids; typically hydrochloric, hydrobromic, hydrofluoric, or hydroiodic acid; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example acetic, propionic, hydroacetic, 2-hydroxypropanoic acid, 2-oxopropanoic acid, ethandioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-l,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic acid,
  • the spacer unit SPU may comprise a number of optionally substituted methylene groups CR 6 R 7 . It is understood by the phrase "each R 6 and each R 7 is optionally and independently selected" that not all R 6 groups may be identical and not all R 7 groups may be identical. Thus, each substituted methylene group may have an R 6 and an R 7 that is different than any other R 6 or R 7 substituents on other methylene groups. In some embodiments, some of R ⁇ or R 7 substituents may be identical in one or more methylene groups.
  • the present invention relates to a compound of Formula I, wherein
  • X is selected from the group consisting of O, N and S;
  • Y 0 or tautomers thereof
  • SPU is a spacer unit providing a distance d between Z and N wherein -SPU- is -(CR 6 R 7 ) n - A-, n is 3, and A is absent;
  • R 1 and R 2 fo ⁇ n a piperidine ring substituted with one or more substituents R 4 selected from the group consisting of hydroxy, halogen, C ⁇ _ 8 -alkyl, C 3 diligent 8 -cycloalkyl, C]. 6 - arylalkyl, Ci- ⁇ -heteroarylalkyl, C]. 8 -alkoxy, C ⁇ profession 8 -heteroalkyl, Q-s-alkylcarbonyl, Q_ 8 -alkylidene, Q_ 8 -alkenyl, C 2 contend 8 -alkynyl, C ⁇ . 6 -all yloxyimino, and C ⁇ . 6 -alkyloxyamino each of which may be optionally substituted with a substituent R 5
  • R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, Q_ 8 -alkyl, Q favor 8 - alkoxy, C 3 _ 8 -cycloalkyl, C 3 . 8 -heterocyclyl, Q-s-alkylcarbonyl, C ⁇ _ 8 -alkylidene, C 2 . 8 -alkenyl and Q_ 8 - alkynyl; C ⁇ _ 8 -heteroalkyl
  • R x may be absent or selected from the group consisting of hydrogen, optionally substituted C ⁇ profession 8 -alkyl
  • R 3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted C ⁇ repay 8 -alkyl, C ⁇ . 8 -alkoxy, optionally substituted C ⁇ . 8 -alkylidene, optionally substituted C 2 . 8 -alkenyl, optionally substituted C 2 _ 8 -alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 . 8 -cycloalkyl, optionally substituted Q_ 8 - heterocyclyl, and optionally substituted C ⁇ .
  • each R 6 and each R 7 is optionally and independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted Q_ 8 -alkyl, C ⁇ _ 8 -aIkoxy, C 3 . 8 -cycloalkyl, Q_ 6 - arylallcyl, Q_ 8 -heteroalkyl
  • the present invention relates to a compound of Formula
  • Y 0 or tautomers thereof
  • SPU is a spacer unit providing a distance d between Z and N wherein -SPU- is -(CR 6 R 7 ) P C ⁇ €-(CR 6 R 7 ) q - or -(CR 6 R 7 ) n -A-, n is 3, p and q are each 1, and A is absent;
  • R 1 and R 2 form a piperidine, ring substituted with one or more substituents R 4 selected from the group consisting of hydroxy, halogen, C 3 _ ⁇ o-aryl, Q- 8 -alkyl, C 3 . 8 -cycloalkyl, Q. 8 -alkoxy, Q_ 8 -heteroalkyl, Q favor 8 -alkylcarbonyl, Q. 8 -alkylidene, C 2 _ 8 -alkenyl, C 2 . 8 -alkynyl, Q_ 6 -all yloxyimino, and Q_ 6 -alkyloxyamino each of which may be optionally substituted with a substituent R 5 ;
  • R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, Q_ 8 -alkyl, Q_ 8 - alkoxy, C 3 . 8 -cycloall yl, C 3 . 8 -heterocyclyl, Q_ 8 -alkylcarbonyl, Q-s-alkylidene, C 2 . 8 -alkenyl and C 2 . 8 - alkynyl;
  • R x may be absent or selected from the group consisting of hydrogen, optionally substituted Cj.s-alkyl
  • R 3 may be present 0-4 times and selected from the group consisting of halogen, hydroxy, optionally substituted Q_ 8 -alkyl, Q_s-alkoxy, optionally substituted Q_ 8 -alkylidene, optionally substituted C 2 . 8 -alkenyl, optionally substituted Q-s-alkynyl optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 . 8 -cycloall yl, optionally substituted C 3 .
  • each R 6 and each R 7 is optionally and independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted Q_ s -alkyl, Q. 8 -alkoxy, Q.s-cycloalkyl.
  • Z may be N (nitrogen).
  • the distance d relates to the distance between the ring nitrogen atom and the nitrogen atom of N(R')R 2 .
  • X may be selected from the group consisting of N, S, and O, preferably N and O. h a preferred embodiment X and Z are both N. In another preferred embodiment X is S and Z is N, while in yet another preferred embodiment X is O and Z is N.
  • Tautomers of the carbonyl and thiocarbonyl moiety are known to the person skilled in the art and are isomers involving migration of the pi system from the exo-cyclic to the endocyclic position.
  • the enolic or thio-enolic derivative may be O- or S-alkylated in a manner known to the person skilled in the art.
  • -Y 0.
  • X is N
  • -Y 0
  • Z is N
  • X is O
  • - Y 0
  • Z is N
  • X is S
  • -Y 0
  • Z is N, resulting in a benzisothiazolone.
  • the moiety Z may be substituted with a spacer unit (SPU).
  • SPU provides a distance d between Z and N.
  • d may be defined in terms of through-bond distances between Z and N of N(R')R 2 or a combination of through-bond and through-space distances between Z and N of N(R')R 2 .
  • -SPU- may be a biradical selected from the group consisting of -(CR 6 R 7 ) n -A-, -C 3 .
  • n, p, and q are independently in the range 0 to 5, such as 0, 1, 2, 3, 4, and 5, and A is absent or an optionally substituted -C 3 . 8 -cycloalkyl.
  • n is in the range 2 to 5, most preferably 2 to 4, such as 2, 3, or 4.
  • the C 3 . 8 -cycloalkyl- ring of -SPU- may be an optionally substituted cyclohexylene.
  • -SPU- may be selected from the group consisting of -(CR 6 R 7 ) n -A- and an optionally substituted cyclohexylene wherein n is in the range 1 to 5, preferably 2 to 5 and A is absent or an optionally substituted cyclohexylene.
  • -SPU- may be an ethylene, propylene, butylene, or pentylene biradical, preferably ethylene, propylene or butylene, each of which may be optionally substituted.
  • -SPU- is a cylcohexylene biradical.
  • -SPU- may be 2-butynylene, 1-propenylene,
  • 2-(2-phenylethyl)propylene 2-phenylpropylene, 2-methylpropylene, 2-ethylpropylene, 2-iso- propylpropylene, 2-methoxypropylene, 2-frifluoromethylpropylene, 2phenylmethylpropylene, 2-fluoropropylene, 2-aminocarbonylpropylene, 2-methoxycarbonylpropylene, and
  • the cyclohexylene of -SPU- may be an optionally substituted
  • N together with R 1 and R 2 may form a heterocyclic ring wherein said heterocyclic ring is selected from the group consisting of perhydroazocine, perhydroazepine,
  • N(R')R 2 is selected from the group consisting of a piperidine, pyrrolidine, azetidine, an Most preferably N(R )R is selected from the group
  • the heterocyclic ring formed by N together with R 1 and R 2 may be substituted with one or more substituents R 4 selected from the group consisting of halogen, hydroxy, Q_ 8 -alkyl, Q_ 8 -heteroalkyl, C 3 . 8 -cycloalkyl, C 3 . 8 -heterocyclyl, Q.io-aryl, C s . ⁇ o-heteroaryl, Q. 6 -arylalkyl, Q favor 6 - heteroarylallyl, Q_ 8 -alkoxy, Q_ 8 -alkylcarbonyl, Q_ 8 -alkylidene, C 2 . 8 -alkenyl, C 2 . 8 -all ⁇ vnyl, Q. 6 - alkyloxyimino, and C ⁇ . 6 -alkyloxyamino each of which may be optionally substituted with a substituent R 5 .
  • R 4 selected from the group consisting of halogen,
  • the heterocyclic ring formed by N together with R 1 and R 2 may be substituted with one more substituent R 4 .
  • the heterocyclic ring may be selected from the group comprising of a piperidine with at least one substituent R 4 in the 2-position, a piperidine with at least one substituent R 4 in the 3-position, a piperidine with at least one substituent R 4 in the 4-position, a pyrrolidine with at least one substituent R 4 in the 3-position, an azetidine with at least one substituent R 4 in the 3-position and an aziridine with at least one substituent R 4 in the 2-position.
  • the heterocyclic ring formed by N together with R 1 and R 2 may also be a
  • N(R ! )R 2 may be selected from the group consisting of a piperidine with at least one substituent R 4 in the 2-position, a piperidine with at least one substituent R 4 in the 3-position, a piperidine with at least one substituent R 4 in the 4-position, most preferably consisting of a piperidine with at least one substituent R 4 in the 4-position.
  • N(R')R 2 may be selected from the group
  • N(R : )R 2 may be defined as
  • each R 4 is independently selected from the group consisting of hydrogen, halogen, hydroxy, Q_ 8 -alkyl, C 3 . 8 -cycloall yl, Q_ 6 -arylalkyl, Q. 8 -alkoxy, Q_ 8 -alkylcarbonyl, Q. 8 -alkylidene, C 2 . 8 -alkenyl, C 2 _ 8 -alkynyl, Q_ 8 -heteroalkyl, C ⁇ . 6 -alkyloxyimino, and Q. 6 -all ⁇ yloxyamino each of which may be optionally substituted with a substituent R 5 , wherein at least one of R 4 is not hydrogen; and
  • R is selected from the group consisting of hydrogen, halogen, hydroxy, Q. 8 -allcyl, C 3 _8-cycloalkyl, Q_s-alkylidene, C 2 . 8 -alkenyl, C 2 _ 8 -alkynyl, Q. 8 -alkoxy and Q_ 8 -heteroalkyl.
  • R 4 may be selected from the group consisting of hydrogen, hydroxy, C 3 . 8 -alkyl, C 3 . 8 -alkoxy, Q. 6 -arylalkyl, C 3 _ 8 -heteroalkyl, and C 3 . 8 -alkylidene, each of which may be optionally substituted with a substituent R 5 , wherein at least one of R 4 is not hydrogen and wherein R 5 is selected from the group consisting of hydrogen, halogen, hydroxy and Q_ 8 -alkyl, Q favor 8 -alkoxy, Q. 8 -heteroalkyl.
  • the one or more substituent R 4 may also be selected from the group consisting of Q- 8 -alkyl, C 3 . 8 -alkoxy, C 3 . 8 -heteroalkyl, Q. 8 -alkylidene, each of which may be optionally substituted with a substituent R 5 .
  • the one or more substituent R 4 may be selected from the group consisting of a Q_8-alkyl, C 3 .
  • R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, Q_ s -alkyl, Q_ 8 -alkoxy and C 3 . 8 - cycloalkyl,
  • R 5 may be selected from the group consisting of hydrogen, halogen, hydroxy, Q. 8 -alkyl, Q. 8 -cycloalkyl, Q_ 8 -alkoxy, C 3 . 8 -heterocyclyl, Q favor 8 -alkylcarbonyl, Q_ g-all ylidene, C 2 . 8 -alkenyl and C 2 . 8 -all ynyl, particularly hydrogen, C]. 8 -alkoxy, halogen and Q_ s - alkyl.
  • R 4 may be selected from the group consisting of ethyloxymethyl, methyloxyethyl, propyloxy, propyl, propylidene, butyl, butylidene, pentyl and pentylidene, each of which may be optionally substituted, hi a most preferred embodiment, R 4 is selected from the group consisting of butyl, pentyl, and propyloxy, each of which may be optionally substituted.
  • embodiments of compound I may be chiral or comprised of one or more chiral centres. Where the compounds according to the invention have at least one chiral center, they may exist as a racemate, enantiomers or diastermeomers. It should be noted that all such isomers and mixtures thereof are included in the scope of the present invention. Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the present invention may form solvates with water (i.e. hydrates) or common organic solvents. Such solvates are also included in the scope of this invention.
  • the processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers
  • such isomers may be separated by conventional techniques such as preparative chiral chromatography.
  • the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by stereoselective synthesis or by resolution.
  • the compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-/7-toluoyl-fi?-tartaric acid and/or (+)-di- ⁇ -toluoyl-/-tartaric acid followed by fractional crystallization and regeneration of the free base.
  • the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
  • any of the processes for preparation of the compounds of the present invention it may be necessary or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • R x is a Q_ 8 -alkyl such as methyl, ethyl, propyl, butyl, pentyl, or hexyl, typically methyl, ethyl or propyl.
  • the compounds according to Formula I are intended for use as a pharmaceutical.
  • a further aspect of the invention relates to a pharmaceutical composition comprising a compound as described herein, together with pharmaceutically acceptable carriers or excipients. Excipients and carriers will depend on, amongst other factors, the route of administration of the compound.
  • Compounds of the present invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever specific pharmacological modification of the activity of muscarinic receptors is required.
  • compositions comprising one or more compounds of Formula I together with a pharmaceutically acceptable diluent or excipient.
  • compositions are in unit dosage forms such as tablets, pills, capsules (including sustained-release or delayed-release formulations), powders, granules, elixirs, tinctures, syrups and emulsions, sterile parenteral solutions or suspensions, aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral (e.g., intravenous, intramuscular or subcutaneous), intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation, and may be formulated in an appropriate manner and in accordance with accepted practices such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton PA, 1990.
  • compositions may be in sustained- release form suitable for once-weeldy or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
  • an insoluble salt of the active compound such as the decanoate salt
  • the present invention also contemplates providing suitable topical formulations for administration to, e.g., eye or sldn or mucosa.
  • the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrating agents, flavoring agents and coloring agents can also be incorporated into the mixture.
  • suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include, without limitation, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • the active ingredient is mixed with a suitable pharmaceutical excipient, e.g., such as the ones described above, and other pharmaceutical diluents, e.g., water, to fo ⁇ n a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
  • a suitable pharmaceutical excipient e.g., such as the ones described above
  • other pharmaceutical diluents e.g., water
  • the tablets or pills of the present composition may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner core containing the active compound and an outer layer as a coating surrounding the core.
  • the outer coating may be an enteric layer, which serves to resist disintegration in the stomach and permits the inner core to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with conventional materials such as shellac, cetyl alcohol and cellulose acetate.
  • the liquid forms in which the present compositions may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical carriers.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, gelatin, methylcellulose or polyvinyl-pyrrolidone.
  • Other dispersing agents, which may be employed, include glycerin and the like.
  • compositions For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations, which generally contain suitable preservatives, are employed when intravenous administration is desired.
  • the compositions can also be formulated as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses two, three or four times daily.
  • compounds for the present invention may be administered in intranasal form via topical use of suitable intranasal vehicles, or via fransdermal routes, using those forms of fransdermal sldn patches well known to persons skilled in the art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed.
  • a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the disease or disorder, which is being treated.
  • the daily dosage of the products may be varied over a wide range from 0.01 to
  • compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0 or 50.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a unit dose typically contains from about 0.001 mg to about 50 mg of the active ingredient, preferably from about 1 mg to about 10 mg of active ingredient.
  • An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0001 mg/kg to about 25 mg/kg of body weight per day.
  • the range is from about 0.001 to 10 mg/kg of body weight per day, and especially from about 0.001 mg/kg to 1 mg/kg of body weight per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day.
  • Compounds according to the present invention may be used alone at appropriate dosages defined by routine testing in order to obtain optimal pharmacological effect on a muscarinic receptor, in particular the muscarinic Mi or M receptor subtype, while minimizing any potential toxic or otherwise unwanted effects.
  • co-administration or sequential administration of other agents, which improve the effect of the compound may, in some cases, be desirable.
  • the pharmacological properties and the selectivity of the compounds of this invention for specific muscarinic receptor subtypes may be demonstrated by a number of different assay methods using recombinant receptor subtypes, preferably of the human receptors if these are available, e.g., conventional second messenger or binding assays.
  • a particularly convenient functional assay system is the receptor selection and amplification assay disclosed in US 5,707,798 describing a method of screening for bioactive compounds by utilizing the ability of cells transfected with receptor DNA, e.g., coding for the different muscarinic subtypes, to amplify in the presence of a ligand of the receptor. Cell amplification is detected as increased levels of a marker also expressed by the cells.
  • An important aspect of the present invention relates to a method of increasing an activity of a cholinergic receptor comprising contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound of Formula I, as defined supra.
  • the present investigators have surprisingly found that the compounds of Fo ⁇ nula I act as cholinergic agonists and, most remarkably, the compounds of Formula I are selective for the either the Mi or M 4 , or both the Mi and M 4 muscarinic receptor subtypes.
  • a further important aspect of the present invention relates to a method of treating or preventing a mental disorder in a mammal, such as a human, comprising the administration of an effective amount of a compound of Formula I.
  • disorders considered to be suitable for treatment by either Mi and/or M 4 agonism, or combined M]/M agonism and dopaminergic D 2 antagonism are selected from the group consisting of cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, and increased intraocular pressure.
  • suitable disorders considered to be suitable and particularly attractive may be selected from the group consisting of neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, attention-deficit disorder, sudden infant death syndrome, and glaucoma.
  • the compounds of this invention are useful in the treatment of mania, bipolar disorder, unipolar disorder, schizoaffective disorder, schizoplireniform disorder and anxiety. It should be noted that other non-schizophrenic causes of psychosis, including drug induced, those associated with dementia and other neurodegenerative disorders (such as Huntington's) are also anticipated to be suitable.
  • the Tic disorders also include a spectrum of disorders including Tourettes and
  • An important aspect of the invention therefore relates to the use of a compound according or a pha ⁇ naceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the preparation of a medicament for the prophylactic or curative treatment of psychosis or alleviation of symptoms associated with psychosis.
  • the medicament acts, at least in part, as an M ! agonist or as Mi and M 4 agonist.
  • the compound according to Formula I may further act as a D 2 antagonist.
  • an important aspect of the invention relates to a use of compounds of Formula I as Mi and M 4 agonist, as well as D 2 antagonists. Illustrative examples of compounds with this combined activity are tabulated in Example 1.
  • Compounds 61KS19, 45NK70, 45NK71, 45NK110, 61KS12 and 61KS13 have high binding efficacy for the Mj and M receptor subtypes. Moreover, compounds of Formula I have high selectivity for the Mi and M 4 receptor subtypes over M 2 , M 3 , M 5 receptor subtypes. Further, compounds of Formula I have D 2 antagonistic activity.
  • muscarinic receptors may be implicated in the control of amyloid precursor processing, in particular by activation of the Mi receptor.
  • a further aspect of the present invention relates to a method of modulating or preventing the progression or formation of amyloid plaques in an individual susceptible to or affected by Alzheimer's Disease by administering an effective amount of a compound of Formula I, said effective amount sufficient to modulate amyloid precursor protein processing.
  • NIH-3T3 cells available from the American Type Culture Collection as ATCC CRL 1658 were transfected with plasmid DNA encoding the ml and m4 receptors and plasmid DNA encoding ⁇ -galactosidase.
  • Transfected cells were grown in the presence of between 1 nM and 40 ⁇ M of the test compound for 5 days. On day 5, the cells were lysed using 0.5% nonidet-P and ⁇ -galactosidase expression was quantified using the chromogenic substrate o-nitrophenyl- ⁇ -D-galactoside (ONGP).
  • UFP chromogenic substrate o-nitrophenyl- ⁇ -D-galactoside
  • Cell membranes expressing the D 2 receptor were prepared by transfecting tSA cells (Chahine, M., Bennet, P. B., George, A. L., Horn, R. (1994) Pfluegers Arch. 427, 136-142) with 10 ⁇ g plasmid DNA encoding the human dopamine D 2 receptor and 40 ⁇ l Superfect (Qiagen). The cells were harvested 48 hours and transfection and membranes were prepared by homogenizing the cells using a Polyfron harvester in 20 mM Hepes, 10 mM EDTA, pH 7.4. The homogenate was centrifuged for 30 minutes at 37,000g.
  • the pellet was homogenized again in 60 ml 20 mM Hepes, 5 mM EDTA. The homogenate was centrifuged for 30 minutes at 37,000g. The supernatant was discarded. The pellet was homogenized again in 10 ml 20 mM Hepes, 1 mM EDTA. The resultant membranes were frozen at -80°C.
  • ligand concentrations between 1 nM and 10 ⁇ M, or haloperidol concentrations between 0.1 nM and 1 ⁇ M in 460 ⁇ l 20 mM Hepes, 1 mM EDTA, 0.1% (w/v) bovine serum albumin.
  • Nonspecific binding was defined as binding in the presence of 1 ⁇ M haloperidol.
  • the membranes were incubated for 4 hours at 37°C, and then filtered onto Packard GFB Filterplates using a Packard harvester. The membranes were dried and 50 ⁇ l Microscint (Packard) was added to each well. The amount of bound radioligand was quantified using a Packard Topcount scintillation counter.
  • % inhibition was defined as (maximum - minimum)/(maximum response of cells to haloperidol).
  • pIC 50 -log (IQo).
  • NT not tested.
  • mice Male Non-Swiss Albino mice (Harlan Sprague-Dawley) were housed (4 mice/cage) in rooms with temperature and humidity controlled and water and food (Harlan Teklad) freely available. Mice were kept on a 12-hr ligh dark cycle. Procedure Locomotor Activity
  • mice were treated with 0.3 mg/kg dizocilpine, 3.0 mg/kg d-amphetamine or 3.0 mg/kg scopolamine i.p. 15 min before the session (15 min after 61KS19).
  • IKS 19 (10 mg/kg) or haloperidol (1 mg/kg) were administered i.p. 60 min before the start of the session.
  • the forepaws of each animal is placed on the rod and the time to step down is measured. If the animal steps off immediately, another attempt is made until the animal stays on for more than 10 sec or 10 attempts have been made. A maximum of 2 min is allowed at which time the animal is taken away from the rod and returned to the homecage.
  • Example 3 Synthetic Procedures 3.1 General preparative LC-MS procedure
  • 600 pumps, 2700 sample manager, 996 PDA detector, ZMD massspecfrometer).
  • TFA in water buffer B was 0.15% TFA in acetonitrile/water 95/5.
  • the columns were operated at 17 ml/min. Following an initial hold of 2.5 min at 30% buffer B, compounds were separated using a gradient af 30-100% buffer B in 8.5 min. A dual column setup with two pumps was used to equilibrate one column, while running on the other.
  • LDA was generated by adding BuLi (20 mL, 1.68M, 32.6 mmol) to a solution of diisopropylamine (2.38 g, 32.6 mmol) in dry THF (lOmL) at -78°C under argon. The mixture was kept at that temperature for 30 min followed by the addition of a solution of N- Bocnortropinone (5.27 g, 23.4 mmol) in dry THF (20 mL). The mixture was then left stirring for lh while maintaining the temperature at 78°C.
  • Trifluorosulfonyl-8-tert-butyloxycarbonyl-8-azabicyclo[3.2.1]-oct-2-ene (104KS22) (0.220 g, 0.616 mmol) were reacted according to GP2 to give the title compound (79KS74) (0.083 g, 54%).
  • Platinium dioxide 200 mg was added to 4-benzylpiperidine (1.75 g, 10 mmol) in EtOH (20 ml) and HC1 in dioxan (20 ml, 4 M). The flask was evacuated, flooded with hydrogen and this procedure was repeated twice. The reaction was stirred vigorously at r.t. for 72 h then platinium oxide (200 mg) was added and the reaction was stirred at r.t. for 18 h. The reaction mixture was filtered through Celite eluting with EtOAc and the solute concentrated in vacuo. Ether (50 ml) was added and the reaction concentrated in vacuo.
  • Platinium dioxide (0.200 g) was added to 4-phenylpiperidine (1.55 g, 10 mmol) in EtOH (40 ml) and HC1 in dioxan (5 ml, 4 M). The flask was evacuated, flooded with hydrogen and this procedure was repeated twice. The reaction was stirred vigorously at r.t. for 72 h then filtered through Celite eluting with EtOAc and the solute was concentrated in vacuo to give a white solid. Water (30 ml) was added followed by sodium hydroxide (20ml, 2 M) and the product was extracted into EtOAc (3x50 ml).
  • the product was purified by flash CC and/or by prep. RP- HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H 2 0/MeCN, ammoniumacetate buffer (25nM)].
  • the product was purified by flash CC (Si0 2 ; EtOAc) and by prep. RP-HPLC [conditions: stationary phase, Luna 15um C18; column, 250x21.2 mm; mobile phase, 20 ml/min, H 2 0/MeCN, ammoniumacetate buffer (25nM)] to give the title compound (92LH60-1A) (0.135 g, 53%).
  • the oxalate salt was prepared by dissolving the product in Et 2 0 and a minimum of MeOH followed by the addition of a solution of oxalic acid (l.leq of obtained product) in Et 2 0. Filtration gave the title compound (61KS89-oxalate). NMR of the free base was recorded.
  • the oxalate salt was prepared by dissolving the product in Et 2 0 and a minimum of MeOH followed by the addition of a solution of oxalic acid (l.leq of obtained product) in Et 2 0. Filtration gave the title compound (61KS91-3-oxalate). NMR of the free base was recorded.
  • the crude product was purified by CC (Si0 2 ; NH 4 OH/MeOH/EtOAc 1:2:17) and added an acidic ionexchange column.
  • the column was washed with MeOH (2 column volumes), thereafter the compound was eluded applying 2 column volumes of an NH 4 OH (25% NH 3 in H 2 0)/MeOH mixture 1:10, and concenfrated.
  • the crude product was further purified by CC (Si0 2 , MeOH/DCM 1:19) followed by CC (Si0 2 ; NH 4 OH/MeOH/EtOAc 1:2:17), and concenfrated.

Abstract

L'invention concerne des composés dérivés de benzimidazolidinone qui augmentent la signalisation ou l'effet de l'acétylcholine dans le cerveau, ainsi que des agonistes muscariniques hautement sélectifs, notamment les sous-types des récepteurs M1 et/ou M4. L'invention concerne également des compositions pharmaceutiques contenant lesdits composés, ainsi que des méthodes de traitement de la psychose utilisant ces composés.
PCT/US2004/009859 2001-10-02 2004-03-30 Derives de benzimidazolidinone utilises en tant qu'agents muscariniques WO2004089942A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32675401P 2001-10-02 2001-10-02
US10/262,517 US7087593B2 (en) 2001-10-02 2002-09-30 Benzimidazolidinone derivatives as muscarinic agents
US40675003A 2003-04-02 2003-04-02
US10/406,750 2003-04-02
US10/408,192 2003-04-03
US10/408,192 US6951849B2 (en) 2001-10-02 2003-04-03 Benzimidazolidinone derivatives as muscarinic agents

Publications (2)

Publication Number Publication Date
WO2004089942A2 true WO2004089942A2 (fr) 2004-10-21
WO2004089942A3 WO2004089942A3 (fr) 2004-11-25

Family

ID=46150402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009859 WO2004089942A2 (fr) 2001-10-02 2004-03-30 Derives de benzimidazolidinone utilises en tant qu'agents muscariniques

Country Status (1)

Country Link
WO (1) WO2004089942A2 (fr)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007036715A3 (fr) * 2005-09-30 2007-05-18 Glaxo Group Ltd Composes exerçant une activite au niveau du recepteur m1 et leurs utilisations en medecine
WO2007142585A1 (fr) * 2006-06-09 2007-12-13 Astrazeneca Ab Agonistes du récepteur muscarinique convenant au traitement de la douleur, de la maladie d'alzheimer et de la schizophrénie
WO2007142583A1 (fr) * 2006-06-09 2007-12-13 Astrazeneca Ab Agonistes des récepteurs muscariniques qui sont efficaces dans le traitement de la douleur, de la maladie d'alzheimer et de la schizophrénie
JP2008514563A (ja) * 2004-09-24 2008-05-08 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
JP2008524328A (ja) * 2004-12-21 2008-07-10 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリン作動薬としてのテトラヒドロキノリン類似体
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
WO2009037293A1 (fr) * 2007-09-20 2009-03-26 Glaxo Group Limited Composés ayant une activité au niveau du récepteur m1 et utilisations de ces derniers en médecine
WO2009037294A1 (fr) * 2007-09-20 2009-03-26 Glaxo Group Limited Composés présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine
WO2009037296A1 (fr) * 2007-09-20 2009-03-26 Glaxo Group Limited Composés qui ont une activité au niveau du récepteur m1 et leurs utilisations en médecine
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
JP2009530347A (ja) * 2006-03-22 2009-08-27 グラクソ グループ リミテッド Ｍ１受容体において活性を有するベンズイミダゾールおよび薬剤におけるそれらの使用
JP2009530348A (ja) * 2006-03-22 2009-08-27 グラクソ グループ リミテッド Ｍ１受容体で活性を有するベンズイミダゾールおよび医薬におけるその使用
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
JP2010521414A (ja) * 2006-03-22 2010-06-24 グラクソ グループ リミテッド Ｍ１受容体で活性を有するベンズイミダゾールおよび医薬におけるその使用
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
EP2258357A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
WO2011063115A1 (fr) 2009-11-19 2011-05-26 Braincells Inc. Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse
WO2011091033A1 (fr) 2010-01-20 2011-07-28 Braincells, Inc. Modulation de la neurogenèse par des agents ppar
EP2377530A2 (fr) 2005-10-21 2011-10-19 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US8288412B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8288413B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
US8541411B2 (en) 2010-10-06 2013-09-24 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
WO2019025099A1 (fr) 2017-08-01 2019-02-07 Merck Patent Gmbh Dérivés de thiazolopyridine utilisés en tant qu'antagonistes du récepteur de l'adénosine
WO2019038215A1 (fr) 2017-08-21 2019-02-28 Merck Patent Gmbh Dérivés de benzimidazole utilisés en tant qu'antagonistes du récepteur de l'adénosine
WO2019038214A1 (fr) 2017-08-21 2019-02-28 Merck Patent Gmbh Dérivés de quinoxaline utilisés en tant qu'antagonistes du récepteur de l'adénosine
WO2020083856A1 (fr) 2018-10-25 2020-04-30 Merck Patent Gmbh Dérivés de 5-azaindazole utilisés en tant qu'antagonistes du récepteur de l'adénosine
WO2020083878A1 (fr) 2018-10-25 2020-04-30 Merck Patent Gmbh Dérivés de 5-azaindazole utilisés en tant qu'antagonistes du récepteur de l'adénosine
WO2020152132A1 (fr) 2019-01-22 2020-07-30 Merck Patent Gmbh Dérivés de thiazolopyridine en tant qu'antagonistes du récepteur de l'adénosine
US11773090B2 (en) 2018-06-22 2023-10-03 Heptares Therapeutics Limited Pharmaceutical compounds
US11793817B2 (en) 2011-11-18 2023-10-24 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
US11834407B2 (en) 2016-10-14 2023-12-05 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US11945801B2 (en) 2018-12-07 2024-04-02 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254127A (en) * 1980-04-03 1981-03-03 Janssen Pharmaceutica, N.V. 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives
WO1996013262A1 (fr) * 1994-10-27 1996-05-09 Merck & Co., Inc. Antagonistes de muscarine
WO1999032481A1 (fr) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
WO2001083472A1 (fr) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Agonistes muscariniques
WO2003028650A2 (fr) * 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Derives de benzimidazolidinone utilises comme agents muscariniques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254127A (en) * 1980-04-03 1981-03-03 Janssen Pharmaceutica, N.V. 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives
WO1996013262A1 (fr) * 1994-10-27 1996-05-09 Merck & Co., Inc. Antagonistes de muscarine
WO1999032481A1 (fr) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
WO2001083472A1 (fr) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Agonistes muscariniques
WO2003028650A2 (fr) * 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Derives de benzimidazolidinone utilises comme agents muscariniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAKIR B ET AL: "SYNTHESIS AND ANTINOCICEPTIVE ACTIVITY OF SOME 3-SUBSTITUTED BENZOTHIAZOLONE DERIVATIVES" FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 54, 1999, pages 846-851, XP001022237 ISSN: 0014-827X cited in the application *

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522906B2 (en) 2001-12-28 2016-12-20 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US8680115B2 (en) 2001-12-28 2014-03-25 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7638512B2 (en) 2004-03-30 2009-12-29 Wyeth Phenylaminopropanol derivatives and methods of their use
JP2008514563A (ja) * 2004-09-24 2008-05-08 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
JP4887297B2 (ja) * 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
JP2008524328A (ja) * 2004-12-21 2008-07-10 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリン作動薬としてのテトラヒドロキノリン類似体
EP2258358A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2258359A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
EP2275096A2 (fr) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2275095A2 (fr) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258357A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US8288412B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
AU2006296369B2 (en) * 2005-09-30 2012-12-20 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8288413B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
WO2007036715A3 (fr) * 2005-09-30 2007-05-18 Glaxo Group Ltd Composes exerçant une activite au niveau du recepteur m1 et leurs utilisations en medecine
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
EA016286B1 (ru) * 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
US8481566B2 (en) 2005-09-30 2013-07-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
EP2377530A2 (fr) 2005-10-21 2011-10-19 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
JP2010521414A (ja) * 2006-03-22 2010-06-24 グラクソ グループ リミテッド Ｍ１受容体で活性を有するベンズイミダゾールおよび医薬におけるその使用
JP2009530348A (ja) * 2006-03-22 2009-08-27 グラクソ グループ リミテッド Ｍ１受容体で活性を有するベンズイミダゾールおよび医薬におけるその使用
JP2009530347A (ja) * 2006-03-22 2009-08-27 グラクソ グループ リミテッド Ｍ１受容体において活性を有するベンズイミダゾールおよび薬剤におけるそれらの使用
EP2382975A2 (fr) 2006-05-09 2011-11-02 Braincells, Inc. Neurogénèse par modulation d'angiotensine
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
WO2007142583A1 (fr) * 2006-06-09 2007-12-13 Astrazeneca Ab Agonistes des récepteurs muscariniques qui sont efficaces dans le traitement de la douleur, de la maladie d'alzheimer et de la schizophrénie
US7956069B2 (en) 2006-06-09 2011-06-07 Astrazeneca Ab Compounds
WO2007142585A1 (fr) * 2006-06-09 2007-12-13 Astrazeneca Ab Agonistes du récepteur muscarinique convenant au traitement de la douleur, de la maladie d'alzheimer et de la schizophrénie
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
WO2009037294A1 (fr) * 2007-09-20 2009-03-26 Glaxo Group Limited Composés présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine
WO2009037296A1 (fr) * 2007-09-20 2009-03-26 Glaxo Group Limited Composés qui ont une activité au niveau du récepteur m1 et leurs utilisations en médecine
US8299257B2 (en) 2007-09-20 2012-10-30 Glaxo Group Limited Compounds which have activity at M1receptor and their uses in medicine
US8344000B2 (en) 2007-09-20 2013-01-01 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2009037293A1 (fr) * 2007-09-20 2009-03-26 Glaxo Group Limited Composés ayant une activité au niveau du récepteur m1 et utilisations de ces derniers en médecine
US8278328B2 (en) 2007-09-20 2012-10-02 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
WO2011063115A1 (fr) 2009-11-19 2011-05-26 Braincells Inc. Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse
WO2011091033A1 (fr) 2010-01-20 2011-07-28 Braincells, Inc. Modulation de la neurogenèse par des agents ppar
US9062003B2 (en) 2010-10-06 2015-06-23 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US10314845B2 (en) 2010-10-06 2019-06-11 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8674090B2 (en) 2010-10-06 2014-03-18 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9156797B2 (en) 2010-10-06 2015-10-13 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8541411B2 (en) 2010-10-06 2013-09-24 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9872860B2 (en) 2010-10-06 2018-01-23 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US10660898B2 (en) 2010-10-06 2020-05-26 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8865912B2 (en) 2010-10-06 2014-10-21 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US11793817B2 (en) 2011-11-18 2023-10-24 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
US11834407B2 (en) 2016-10-14 2023-12-05 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
WO2019025099A1 (fr) 2017-08-01 2019-02-07 Merck Patent Gmbh Dérivés de thiazolopyridine utilisés en tant qu'antagonistes du récepteur de l'adénosine
WO2019038214A1 (fr) 2017-08-21 2019-02-28 Merck Patent Gmbh Dérivés de quinoxaline utilisés en tant qu'antagonistes du récepteur de l'adénosine
WO2019038215A1 (fr) 2017-08-21 2019-02-28 Merck Patent Gmbh Dérivés de benzimidazole utilisés en tant qu'antagonistes du récepteur de l'adénosine
US11773090B2 (en) 2018-06-22 2023-10-03 Heptares Therapeutics Limited Pharmaceutical compounds
WO2020083856A1 (fr) 2018-10-25 2020-04-30 Merck Patent Gmbh Dérivés de 5-azaindazole utilisés en tant qu'antagonistes du récepteur de l'adénosine
WO2020083878A1 (fr) 2018-10-25 2020-04-30 Merck Patent Gmbh Dérivés de 5-azaindazole utilisés en tant qu'antagonistes du récepteur de l'adénosine
US11945801B2 (en) 2018-12-07 2024-04-02 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists
WO2020152132A1 (fr) 2019-01-22 2020-07-30 Merck Patent Gmbh Dérivés de thiazolopyridine en tant qu'antagonistes du récepteur de l'adénosine

Also Published As

Publication number Publication date
WO2004089942A3 (fr) 2004-11-25

Similar Documents

Publication Publication Date Title
US7291611B2 (en) Benzimidazolidinone derivatives as muscarinic agents
US7273857B2 (en) Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (fr) Derives de benzimidazolidinone utilises en tant qu&#39;agents muscariniques
AU2002327810A1 (en) Benzimidazolidinone derivatives as muscarinic agents
US7576078B2 (en) Tetrahydroquinoline analogues as muscarinic agonists
US8680115B2 (en) Tetrahydroquinoline analogues as muscarinic agonists
JP2005535655A (ja) ムスカリン性受容体拮抗剤としてのアザビシクロ誘導体
JP2010519193A (ja) Ｍ３ムスカリン受容体としての複素環式誘導体
US7446123B2 (en) Azabicyclo derivatives as muscarinic receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase